Great Ormond Street Hospital for Children NHS Foundation Trust

Ananda Developments Plc presents interim results for the period ending 31 July 2024, focusing on advancing clinical trials for CBD-based treatments in chronic inflammatory pain conditions, chemotherapy-induced nerve pain, endometriosis, and refractory epilepsies. The company reports a loss of £1,213,270 before tax, with net liabilities of £860,309, and announces a £2.2m capital raising, with £2m invested by Chairman Charles Morgan. Ananda's MRX1 CBD formulation shows significant cardioprotective effects in a pre-clinical study for heart failure with preserved ejection fraction (HFpEF).

NHS trials on cannabis-based medicines for severe epilepsy, delayed since 2019, face criticism for focusing on CBD and THC isolates, ignoring full-spectrum products, and requiring dangerous 'washout periods'.